关注
Mohamed Alaa Gouda
Mohamed Alaa Gouda
其他姓名Mohamed Gouda
The University of Texas MD Anderson Cancer Center
在 mdanderson.org 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors
MA Gouda, V Subbiah
American Society of Clinical Oncology Educational Book 43, e404770, 2023
332023
Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
MA Gouda, V Subbiah
ESMO open 8 (2), 100788, 2023
332023
Tumor-agnostic precision medicine from the AACR GENIE database: clinical implications
MA Gouda, BE Nelson, L Buschhorn, A Wahida, V Subbiah
Clinical Cancer Research 29 (15), 2753-2760, 2023
292023
Medical Undergraduates' Contributions to Publication Output of World's Top Universities in 2013
MA Gouda, HS Zidan, AA Marey, MG Gameal, RG Elmahrook, A Saleh, ...
QJM, 2016
252016
Family medicine in Egypt from medical students' perspective: a nationwide survey
MM AlKot, MA Gouda, MT KhalafAllah, MS Zahran, MM Kallaf, AM Zayed
Teaching and learning in medicine 27 (3), 264-273, 2015
222015
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers
MA Gouda, HJ Huang, SA Piha-Paul, SG Call, DD Karp, S Fu, A Naing, ...
JCO Precision Oncology 6, e2100512, 2022
192022
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate …
M Lapin, HJ Huang, S Chagani, M Javle, RT Shroff, S Pant, MA Gouda, ...
JCO Precision Oncology 6, e2100197, 2022
152022
Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma
MA Gouda, J Polivka, HJ Huang, I Treskova, K Pivovarcikova, T Fikrle, ...
ESMO Open 7 (1), 100357, 2022
152022
N-of-1 Trials in Cancer Drug Development
MA Gouda, L Buschhorn, A Schneeweiss, A Wahida, V Subbiah
Cancer Discovery 13 (6), 1301-1309, 2023
132023
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)
MA Gouda, F Janku, A Wahida, L Buschhorn, A Schneeweiss, NA Karim, ...
Annals of Oncology, 2023
112023
Student research in arab world: what is the current state?
OA Aboshady, MA Gouda
Saudi medical journal 37 (6), 707, 2016
112016
ALK fusions in the pan-cancer setting: another tumor-agnostic target?
A Shreenivas, F Janku, MA Gouda, HZ Chen, B George, S Kato, ...
npj Precision Oncology 7 (1), 101, 2023
102023
Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer
FM Johnson, F Janku, MA Gouda, HT Tran, JD Kawedia, D Schmitz, ...
The Oncologist 27 (12), 1004-e926, 2022
102022
Ultrasensitive detection of BRAF V600E mutations in circulating tumor DNA of patients with metastatic thyroid cancer
MA Gouda, E Ong, HJ Huang, LW McPhaul, S Yoon, F Janku, ...
Endocrine 76 (2), 491-494, 2022
92022
Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
MA Gouda, V Subbiah
Therapeutic Advances in Medical Oncology 15, 17588359231177015, 2023
82023
Pros and cons of student journals
OA Aboshady, MA Gouda
Perspectives on Medical Education, 1-2, 2016
52016
Pearls and pitfalls of ChatGPT in medical oncology
J Blum, AK Menta, X Zhao, VB Yang, MA Gouda, V Subbiah
Trends in Cancer, 2023
42023
Precision oncology for biliary tract tumors: it’s written in blood!
MA Gouda, V Subbiah
Annals of Oncology 33 (12), 1209-1211, 2022
42022
529MO Activity, safety and circulating tumour DNA (ctDNA) dynamics of paradox breaker BRAF inhibitor PLX8394 in patients with advanced cancer
MA Gouda, EJ Sherman, GW Gilcrease, UN Vaishampayan, A Parikh, ...
Annals of Oncology 31, S465, 2020
32020
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer
V Subbiah, MA Gouda, JB Iorgulescu, R Dadu, K Patel, S Sherman, ...
NPJ Precision Oncology 8 (1), 62, 2024
22024
系统目前无法执行此操作,请稍后再试。
文章 1–20